[Form 4] IONIS PHARMACEUTICALS INC Insider Trading Activity
Rhea-AI Filing Summary
Ionis Pharmaceuticals EVP Research Eric Swayze reported multiple stock option exercises and related share sales on 01/02/2026. He exercised options for 5,125 and 18,338 shares of common stock at an exercise price of $60.89 per share and sold the same numbers of shares at weighted average prices of $78.57 and $79.27, respectively, under a Rule 10b5-1 trading plan.
After these transactions, Swayze held 30,453 Ionis common shares directly and 256 shares indirectly through his son. He also received a new grant of non-qualified stock options for 19,350 shares at an exercise price of $79.67, vesting 25% on 01/02/2027 with the rest vesting in 36 monthly installments over three years, while his son received options for 150 shares on the same terms, reported as indirectly owned.
Positive
- None.
Negative
- None.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Exercise | Non-Qualified Stock Option (right to buy) | 5,125 | $0.00 | -- |
| Exercise | Non-Qualified Stock Option (right to buy) | 18,338 | $0.00 | -- |
| Grant/Award | Non-Qualified Stock Option (right to buy) | 19,350 | $0.00 | -- |
| Grant/Award | Non-Qualified Stock Option (right to buy) | 150 | $0.00 | -- |
| Exercise | Common Stock | 5,125 | $60.89 | $312K |
| Sale | Common Stock | 5,125 | $78.57 | $403K |
| Exercise | Common Stock | 18,338 | $60.89 | $1.12M |
| Sale | Common Stock | 18,338 | $79.27 | $1.45M |
| holding | Common Stock | -- | -- | -- |
Footnotes (1)
- Shares sold pursuant to a Rule 10b5-1 Trading Plan adopted by the reporting person on August 14, 2024. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $78.155 to $78.88 inclusive. The reporting person undertakes to provide to Ionis Pharmaceuticals, Inc. any security holder of Ionis Pharmaceuticals, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) on this Form 4. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $78.88 to $79.70 inclusive. The reporting person undertakes to provide to Ionis Pharmaceuticals, Inc. any security holder of Ionis Pharmaceuticals, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (3) on this Form 4. Grant on 01/02/2026 to reporting person of stock options under the Ionis Pharmaceuticals, Inc. Amended and Restated 2011 Equity Incentive Plan. Following this transaction, the option was exercisable as to 0 shares on 01/02/2026. 25% of the shares subject to the option will vest and become exercisable on 01/02/2027. Thereafter, the remaining shares subject to the option will vest and become exercisable in 36 equal monthly installments over the next 3 years. Grant on 01/02/2026 to reporting person's son of stock options under the Ionis Pharmaceuticals, Inc. Amended and Restated 2011 Equity Incentive Plan. Following this transaction, the option was exercisable as to 0 shares on 01/02/2026. 25% of the shares subject to the option will vest and become exercisable on 01/02/2027. Thereafter, the remaining shares subject to the option will vest and become exercisable in 36 equal monthly installments over the next 3 years.
